drugset / Trial / NCT05772273
PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT
Recruiting
43 enrolled
The First Affiliated Hospital of Soochow University
Jiangsu HengRui Medicine Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This study aims to evaluate the efficacy and safety of PD-1 inhibitor, Azacitidine, and low-dose DLI in AML relapse After allogeneic hematopoietic stem cell transplantation
Timeline
- Start
- 2023-03-15
- Primary completion
- 2026-07-01
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 75 mg/m2 | Subcutaneous |
| Subject | Camrelizumab | Monoclonal antibody | 100 mg | Intravenous |
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |